Ticker Details
Syros Pharmaceuticals, Inc. Syros Pharmaceuticals Inc is a biopharmaceutical company engaged in the understanding of the region of the genome controlling the activation and repression of genes. The companies lead candidates are SY-1425 and SY-1365.
IPO Date:	June 30, 2016
Sector:	Healthcare
Industry:	Biotech
Activated in VL:	False

Average Daily Range
Avg Daily Range:	$0.27 | 4.18%
Avg Daily Range (30 D):	$0.01 | 74.07%
Avg Daily Range (90 D):	$0.01 | 58.33%

Institutional Daily Volume
Avg Daily Volume:	1.01M
Avg Daily Volume (30 D):	.03M
Avg Daily Volume (90 D):	.11M

Trade Size
Avg Trade Size (Sh.):	370
Avg Trade Size (Sh.) (30 D):	797
Avg Trade Size (Sh.) (90 D):	1,499

Institutional Trades
Total Institutional Trades:	229
Avg Institutional Trade:	$1.68M
Avg Institutional Trade (30 D):	$2M
Avg Institutional Trade (90 D):	$2M
Avg Institutional Trade Volume:	.03M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.85M
Avg Closing Trade (30 D):	$M
Avg Closing Trade (90 D):	$M
Avg Closing Volume:	24.57K

News

May 12, 2025 @ 5:00 PM Blood Cancer Treatment Market Sees Accelerated Gro... Source: Delveinsight

Jul 3, 2024 @ 3:35 AM Syros pharmaceuticals director sells $178k in comp... Source: Investing.Com

May 8, 2024 @ 12:15 PM 2seventy bio, Inc. (TSVT) Reports Q1 Loss, Tops Re... Source: Zacks Equity Research

May 2, 2024 @ 2:01 PM Will Femasys Inc. (FEMY) Report Negative Q1 Earnin... Source: Zacks Equity Research

May 1, 2024 @ 2:01 PM Analysts Estimate Syros Pharmaceuticals, Inc. (SYR... Source: Zacks Equity Research

Financials
	TTM	Q3 2024	Q2 2024
Basic EPS	$-3.07	$-.16	$-.59
Diluted EPS	$-3.07	$-.16	$-.59
Revenue	$.39M	$M	$M
Gross Profit
Net Income / Loss	$-97.82M	$-6.4M	$-23.33M
Operating Income / Loss	$-111.66M	$-26.18M	$-27.42M
Cost of Revenue
Net Cash Flow	$-54.91M	$-20.69M	$-4.56M
PE Ratio